Shares of AnaptysBio fell more than 5% on Friday after the U.S. drug developer and GSK's oncology unit, Tesaro, filed lawsuits against each other, with both claiming a breach of a partnership deal for a cancer drug.

DAYS spoilers tease that “something old will hold a key clue” — and in Salem, that means some serious drama is on the way!

From Will Horton and Sonny Kiriakis’s groundbreaking wedding (and controversial tragedy) to Leo Stark and Javi Hernandez stepping up as foster dads to Baby Tesaro. Salem’s queer characters aren’t perf...

Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a partnership deal for a cancer drug.

Sophia Choi is quietly launching a full assault on Johnny DiMera and Chanel Dupree's adoption of Baby Tesaro.

DAYS spoilers tease a massive blackout traps characters together, setting the stage for confessions, betrayals, and maybe even a death.

GSK subsidiary Tesaro and AnaptysBio file dueling lawsuits in Delaware court over alleged breaches of their 2014 Jemperli licensing agreement, with trial set for July 2026.

GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s cobolimab has b...

A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.

A spat between GSK/Tesaro and AnaptysBio over cancer drug Jemperli has escalated into litigation, with both parties claiming breach of contract.

Plus, news about AstraZeneca, AbelZeta, Novavax, Pfizer, Alteogen, Tesaro, Epidarex Capital and Boundless Bio.

GSK's Tesaro and AnaptysBio sue each other over Jemperli licensing deal, with Tesaro seeking to end agreement and AnaptysBio claiming breach of contract obligations.

While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to eliminate the virus, allowing it to persist...

GSK's Tesaro and AnaptysBio sue each other over Jemperli licensing deal, with Tesaro seeking to end agreement and AnaptysBio claiming breach of contract obligations.

Reported Monday, Apr 27 - 6:37am EDT (TheFly subscription required to read more.)

Reported Friday, Apr 24 - 3:45pm EDT (TheFly subscription required to read more.)

Reported Friday, Nov 21 - 5:05am EST (TheFly subscription required to read more.)

Investing.com -- AnaptysBio Inc (NASDAQ:ANAB) stock dropped 11.1% in premarket trading Friday after the clinical-stage biotechnology company announced it has filed a lawsuit against TESARO, Inc., a unit of GSK (NYSE:GSK), for allegedly breaching their collaboration agreement. The company’s complaint, filed in Delaware Chancery Court, contends that TESARO violated exclusivity obligations by participating in clinical trials with competing PD-1 antagonists, including Keytruda. AnaptysBio also claims TESARO failed to use "Commercially Reasonable Efforts" to obtain optimal commercial returns for Jemperli, the drug developed under their partnership. This legal action follows a similar complaint filed by AnaptysBio in 2020, which resulted in a settlement including cash payment and increased royalties. The current dispute emerged after TESARO initiated its own lawsuit against AnaptysBio on November 20, claiming AnaptysBio breached their agreement. Both parties have requested an expedited schedule with trial anticipated in July 2026. Milestone and royalty payments to AnaptysBio will continue during the proceedings. Under the collaboration agreement signed in March 2014, AnaptysBio is eligible to receive tiered royalties on Jemperli sales ranging from 8% to 25% depending on sales volume. The company expects to accrue a $75 million commercial sales milestone in Q4 2025 when Jemperli reaches $1 billion in worldwide net sales. Currently, Jemperli receivables are payable to Sagard due to prior monetizations, with AnaptysBio estimating Sagard will have accrued $250 million in royalties and sales milestones through year-end 2025. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Which stock should you buy in your very next trade? AI computing powers are changing the stock market. Investing.com's ProPicks AI includes dozens of winning stock portfolios chosen by our advanced AI. Year to date, 3 out of 4 global portfolios are beating their benchmark indexes, with 98% in the green. Our flagship Tech Titans strategy doubled the S&P 500 within 18 months, including notable winners like Super Micro Computer (+185%) and AppLovin (+157%). Which stock will be the next to soar?

GSK subsidiary TESARO sues AnaptysBio over cancer drug licensing dispute